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Results of polytetrafluoroethylene-covered nitinol
stents crossing the inguinal ligament
Keith D. Calligaro, MD,a Praveen Balraj, MD,a Neil Moudgill, MD,b Atul Rao, MD,b
Matthew J. Dougherty, MD,a and Joshua Eisenberg, MD,b Philadelphia, Pa
Objective: Placement of arterial endoprostheses across the inguinal ligament is generally thought to be contraindicated for
fear of device kinking, fracture, or occlusion and possible obliteration of the deep femoral artery (DFA). We present a
series of selected patients who underwent insertion of polytetrafluoroethylene-covered nitinol stents (Viabahn stent
grafts. W. L. Gore and Associates Inc, Flagstaff, Ariz) crossing themiddle common femoral artery (CFA) on an emergency
basis or who were considered high risk for open surgery.
Methods:We treated 16 patients with 17 lesions adjacent to or within the CFA with stent grafts that originated in the
common iliac (two) or external iliac (15) artery and terminated in the distal CFA (12), DFA (three), or superficial
femoral (two) artery. Stent grafts were placed on an elective (10) or emergency (seven) basis for arterial occlusive
disease (10), bleeding (six), and aneurysmal disease (one). Comorbidities favoring endovascular treatment were high
medical risk (10) previous scarring (four), morbid obesity (two), and dense arterial calcification precluding open
surgical repair (one).
Results: The DFA was deliberately sacrificed in one of the 17 cases. No patient suffered major complications after the
procedure. All grafts remained patent based on duplex ultrasound imaging during follow-up (mean, 12.3 months;
range, 1-58 months). Two patients required an additional endovascular intervention to treat inflow or outflow
stenoses during follow-up, yielding a 2-year primary patency rate of 93.8% and assisted primary patency rate of
100%.
Conclusions: These results suggest that selective placement of Viabahn stent grafts across the inguinal ligament to treat
arterial occlusive disease or bleeding may prove to be safe, effective, and associated with acceptable patency rates. This
strategy helps avoid complicated open arterial surgery in high-risk patients with associated multiple medical risk factors
or hostile scarred groins. ( J Vasc Surg 2013;57:421-6.)
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tEndovascular therapy has gained widespread accep-
tance to treat many arterial occlusive or aneurysmal
lesions. However, when the common femoral artery
(CFA) is involved, surgical endarterectomy or bypass
remains the preferred treatment.1 Vascular specialists
generally consider placement of stents or stent grafts
(covered stents, endografts) across the inguinal ligament
to be contraindicated for fear of kinking, fracture, or
development of intimal hyperplasia resulting in occlu-
sion of the device or possibly of the deep femoral artery
(DFA).2,3 We report results for stent grafts placed across
the inguinal ligament to treat occlusive disease or bleed-
ing involving the CFA.
METHODS
This is a retrospective analysis of a prospectively main-
tained database of patients undergoing stent graft implants
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http://dx.doi.org/10.1016/j.jvs.2012.05.112o treat lesions involving the CFA between January 1,
005, and December 31, 2010. All lesions were treated
ith polytetrafluoroethylene (PTFE)-covered nitinol
tents, which have an ultrathin PTFE wall, a bonding film,
nd nitinol support (Viabahn, W. L. Gore and Associates
nc, Flagstaff, Ariz). Stent grafts traversed the inguinal
igament in all cases. The inguinal ligament was defined by
line between the pubic tubercle on the superior pelvic
amus to the anterior superior iliac spine of the iliac crest.
e treated 16 patients with 17 lesions (one bilateral;
able I).
Stent grafts ranged in diameter from 6 to 10 mm and
engths from 2.5 to 15 cm. Sizing was based on a caliper or
oronary dilator placed on the skin surface under the fluo-
oscope using roadmapping of the arterial image. Occa-
ionally, there were size discrepancies between the larger
nflow arteries and the smaller outflow arteries, namely,
hen the superficial femoral artery (SFA) and DFA were
he distal attachment site. However, most external iliac
rtery (EIA) diameters were 6 to 7 mm, and most DFA or
FA diameters were 5 to 7 mm, so the differences were not
ery significant.
All stent grafts underwent postdeployment balloon dil-
tation. All procedures were performed by vascular sur-
eons in hybrid endovascular operating rooms with fixed-
maging fluoroscopy. No patient at either institution was
reated during this period with a bare-metal stent crossing
he inguinal ligament.
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February 2013422 Calligaro et alIndications for placing stent grafts across the inguinal
ligament were arterial occlusive disease in 10 patients,
bleeding in six, and aneurysmal dilatation of a previously
placed vein graft in one (Figs 1-4). Predilation of severely
stenotic lesions was performed when necessary to ensure
successful passage of the stent graft across the lesion. None
of these patients was initially treated with balloon angio-
plasty alone as the sole intended initial intervention that
Table I. Characteristics of 16 patients with 17 lesions
Variable No. or mean (range)
Age, years 69.5 (55-85)
Males 10
Hypertension 13
Smoking 9
Hyperlipidemia 8
Diabetes mellitus 8
Indications
Claudication 5
Bleeding (catheterizations) 4
Rest pain 2
Pseudoaneurysm 2
Ischemic toe ulcer 1
Failing limb of aortobifemoral graft 1
Failing femoropopliteal graft 1
Attempted endovascular repair 1
Fig 1. Arteriogram demonstrates active bleeding (arrow) from
the proximal common femoral artery (CFA) secondary to cathe-
terization by neuroradiology in a 67-year-old morbidly obese
woman with hemodynamic instability.went on to develop worsening stenosis. Ten procedures tere performed electively, and seven were performed as
mergencies for bleeding or for unexpected problems that
rose while treating occlusive disease with endovascular
nterventions.
Endovascular therapy was performed instead of open
emoral endarterectomy because of multiple comorbidities
nd high medical risk (10 cases), previous surgery with
evere groin scarring (four cases), morbid obesity (two
ases), and dense calcifications that prevented arterial
lamping at the site of bleeding (one case). The stent grafts
riginated in the CIA in two cases and the EIA in 15 (Table
I). The stent grafts terminated in the distal CFA in 12
ases, the DFA in three (all three with chronic SFA occlu-
ions), and the SFA in two. In one of the latter two patients,
he DFAwas chronically occluded. In the other patient, the
FA was deliberately sacrificed to emergently control a
leeding CFA during an endovascular repair, where arterial
lamping was not possible due to dense calcification. A soft,
oncalcified site in the more distal SFA was accessed by
xtending the longitudinal open groin incision, and the
tent graft was deployed across the CFA occluding the
FA.
Initially, we attempted to insert an 18-mm-diameter
heath for subsequent aortic stent graft placement through
ig 2. Successful endovascular treatment of bleeding after con-
ralateral groin sheath insertion with placement of 7-mm-diameter
.5-cm-long and 8-mm-diameter  2.5-cm-long Viabahn en-
ografts (arrows) into the distal common femoral artery (CFA).he densely calcified plaque rather than through the soft
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Volume 57, Number 2 Calligaro et al 423spot later identified because we initially believed we would
be able to oversew the entry site in the calcified segment
with a large Prolene (Ethicon, Somerville, NJ) suture. We
also initially thought the entire artery would be densely
calcified and only found the 1-cm-long soft SFA segment
after searching the more distal SFA through an extended
groin incision out of necessity because the patient was
bleeding to death. We have since learned our lesson. In all
other procedures, the contralateral CFA was chosen as the
access site.
Follow-up of all patients included clinical examination,
pulse volume recordings with segmental pressures, and
color duplex ultrasound imaging of the stent graft and
inflow and outflow arteries1week after discharge, every 3
months the first year, and then every 6 months.
Patency rates were estimated using Kaplan-Meier
curve and were based on a per-graft analysis. SPSS 15.0
software (SPSS Inc, Chicago, Ill) was used for statistical
analysis, where P  .05 was considered statistically sig-
Fig 3. Arteriogram demonstrates severe atherosclerotic occlusive
disease in the distal external iliac artery (EIA) and common femoral
artery (CFA) (arrow) in an 80-year-old woman with severe cardiac
disease not cleared by cardiology for general anesthesia and with a
nonhealing foot wound.nificant. mESULTS
There was no peri-interventional mortality. Techni-
al success was achieved in all 17 cases. There were no
ajor complications other than deliberate sacrifice of the
FA in one patient to emergently treat a bleeding CFA.
his patient did not suffer any long-term ill effects of this
ntervention, despite sacrificing the DFA. All stent grafts
emained patent, without evidence of stenosis or kinking
nder the inguinal ligament or at any other site in the
raft during follow-up (mean, 12.3 months; range, 1-58
ig 4. Successful endovascular treatment of severe atheroscle-
otic occlusive disease after contralateral groin sheath insertion
ith placement of a 7-mm-diameter  5-cm-long Viabahn en-
ograft into the distal external iliac artery (EIA) and common
emoral artery (CFA), along with placement of a stent in the
roximal superficial femoral artery (SFA) (arrows).
able II. Proximal and distal attachment sites of
olytetrafluoroethylene (PTFE)-covered nitinol stents
rossing the inguinal ligament
rtery No. Details
IA–distal CFA 2 IIAs chronically occluded
IA–distal CFA 10
IA–DFA 3 SFAs chronically occluded
FA 2 1 DFA chronically occluded
1 SFA sacrificed for bleeding during
endovascular repair
FA, Common femoral artery; CIA, common iliac artery; DFA, deep
emoral artery; EIA, external iliac artery; IIA, internal iliac artery; SFA,
uperficial femoral artery.onths). Two limbs required inflow (EIA) or outflow
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February 2013424 Calligaro et al(SFA) interventions consisting of balloon angioplasty
and stenting to maintain patency of the stent grafts
during follow-up, yielding a 2-year primary patency rate
of 93.8% and an assisted primary patency rate of 100%
(Fig 5). These progressive stenotic arterial lesions were
detected in asymptomatic patients by worsening serial
duplex ultrasound imaging. In these two cases, stent
grafts had been inserted for occlusive disease, and the
peak systolic velocity in the EIA and SFA lesions steadily
increased to the point where the peak systolic velocity
was 400 cm/s. We were concerned that such stenotic
lesions would result in low flow and, potentially, occlu-
sion of the stent grafts.
DISCUSSION
Insertion of stents and stent grafts has gained wide
acceptance to treat various arterial lesions, including occlu-
sive disease, aneurysms, pseudoaneurysms, and acute
bleeding in the aorta and peripheral arteries. However,
most interventionalists hesitate to treat lesions in the CFA
using stents or stent grafts primarily for two reasons. When
a stent or stent graft crosses a joint, the possibility of
repeated or prolonged flexion of the device might result in
kinking or accelerated intimal hyperplasia. Subsequent oc-
clusion may lead to critical acute limb ischemia. Addition-
ally, occlusion of the DFA can result if a stent graft crosses
the distal CFA, depriving the lower limb of its primary
dominant collateral.
Nonetheless, treating occlusive or bleeding lesions in
the CFA with a stent or stent graft is an appealing option if
these issues can be avoided. Traditional treatment of these
lesions with open surgery, such as endarterectomy or by-
pass, also carries risk of minor (6.6%-17.7%) and major
(0%-1.8%) complications, including infection, nerve injury,
bleeding, adverse cardiac events, and incisional pain, espe-
cially in obese patients or those with extensively scarred
Fig 5. Primary and assisted primary patency rates of 17 Viabahn
endografts crossing the inguinal ligament.groins.4,5 sWe chose PTFE-covered nitinol stents in preference to
are-metal stents to selectively treat lesions adjacent to or
nvolving the CFA for several reasons. First, nitinol has
ualities that are potentially useful when crossing a joint.6
itinol is a metallic compound (alloy) of titanium and
ickel that is self-expanding when exposed to body temper-
ture. This material is superelastic and resilient. Because the
tent does not expand to its preset shape, it continues to
xert a chronic outward force and resist external compres-
ion. The outward force of a nitinol stent placed without
revious balloon angioplasty may cause the vessel to re-
odel with less intimal hyperplasia than if balloon angio-
lasty was performed before stenting. Kink resistance is also
n important feature of nitinol. Although they do not
ypically have the buckling strength of stainless steel stents,
itinol stents or stent grafts cannot be permanently de-
ormed through external forces. Bauman et al7 reported a
onrandomized series of 98 patients treated for CFA oc-
lusive disease treated with balloon angioplasty alone or
ith balloon-expandable or self-expandable stents and
ound that lesions that were stented demonstrated better
atency rates with a trend toward better results with self-
xpanding nitinol stents. Raju et al8 reported excellent
atency rates of stainless steel stents (Wallstents; Boston
cientific, Natick, Mass) crossing the inguinal ligament to
reat occlusive venous lesions, although it is questionable
hether results of venous stents can be applied to arterial
tents in the same region. They concluded that patency
ates of venous stents were not related to placement of the
tent across the inguinal ligament.
For these reasons, bare-metal stents, particularly nitinol
tents, may be appealing to use across a joint such as the
FA at the hip and the popliteal artery at the knee. How-
ver, there have been many reports of stent fracture, kink-
ng, or compression when uncovered stents are placed
cross a joint.3,9,10 These complications have primarily
ccurred after insertion into the popliteal artery crossing
he knee joint. Possible reasons why stent grafts may per-
orm better than bare-metal stents to treat CFA lesions
nclude clinical evidence showing acceptable patency rates
f stent grafts crossing the popliteal artery, basic science
vidence showing that stent grafts develop less intimal
yperplasia than bare-metal stents, and the fact that bare-
etal stents are not suitable to treat bleeding lesions or
neurysms.
Stent grafts placed across the knee joint have been
hown to yield reasonable patency rates to treat popliteal
rtery aneurysms. Midy et al11 reviewed 42 popliteal artery
neurysms treated with Hemobahn/Viabahn stent grafts
nd reported 80% primary patency rate after a mean
ollow-up of 3 years. Tielliu et al12 reviewed 78 popliteal
rtery aneurysms in 64 patients treated with stent grafts and
eported a primary patency for the nonfractured stent
roup of 73% at 5 years compared with 60% for the frac-
ured stent group, although the cumulative primary pa-
ency rate was not different for the fracture group com-
ared with the nonfracture group. These and other studies
uggest that the long-term patency of PTFE-covered ni-
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Volume 57, Number 2 Calligaro et al 425tinol stents to treat popliteal artery aneurysms is very prom-
ising, especially in larger-diameter arteries commonly
found in these patients. Similarly, CFA lesions that may be
amenable to treatment with stent grafts typically have large-
diameter arteries, ranging from 5 to 8mm formost external
iliac, common femoral, and proximal superficial femoral
arteries.
Another potential advantage of covered stents over
bare-metal stents is that the PTFE covering may provide a
mechanical barrier to the development of intimal hyperpla-
sia within the stent. Investigators tested three different
porosities of expanded PTFE-covered stents and bare
stents using an animal model examining restenosis.13 Neo-
intimal hyperplasia was greatest at the middle of bare stents
where balloon injury was centered. When the center of the
covered stents was evaluated, neointimal development in
both the medium-porosity and high-porosity covered
stents was significantly less than that of thematched control
bare-metal stents. When a bare-metal stent is used, the
stent may penetrate part of the arterial wall, cause damage,
and thereby induce intimal hyperplasia, whereas the PTFE
covering protects the arterial wall from this adverse action.
The authors concluded that expanded PTFE-covered
stents with medium or high porosity could potentially limit
restenosis compared with bare-metal stents, although nar-
rowing can still occur at the ends of the stent grafts.
A third advantage of using covered stents instead of
bare-metal stents is to treat aneurysms, pseudoaneurysms,
or active bleeding sites near the CFA.14 Bleeding will not
be contained by bare-metal stents because blood will leak
through the stent pores.
If larger series with longer-term follow-up support
our findings, the potential to treat aortoiliac disease
extending into the groin solely with percutaneous inter-
vention increases tremendously. As newer devices
emerge to treat juxtarenal and pararenal aortic aneu-
rysms with fenestrated grafts or with adjunctive visceral
or renal artery stent grafts, then vascular surgeons may be
able to treat complicated occlusive lesions extending
throughout the CFA with a variant of stent graft devices.
For instance, potentially a smaller bifurcated stent graft
may be developed with a proximal attachment site in the
EIA and with limbs extending into the SFA and DFA. If
so, the need for open surgical endarterectomy of the
CFA may become a thing of the past. It remains to be
seen whether such complicated devices would be resis-
tant to kinking or occlusion, but treating aortic aneu-
rysms with stent grafts was initially met with a great deal
of skepticism, also. Nonetheless, until such devices are
investigated, femoral endarterectomy remains a relatively
simple procedure with low morbidity and mortality.
Also, we do not advocate inserting bare-metal stents
across the inguinal ligament.
Our report has several weaknesses. The number of
patients and follow-up is limited. We treated patients on a
very selective basis, including some patients with occlusive
disease who developed a dissection or suboptimal result
near the CFA when treated with balloon angioplasty. Sim-larly, patients with aneurysms, pseudoaneurysms, or bleed-
ng near the CFA were treated selectively because of con-
erns regarding open surgery, such as morbid obesity, high
edical risk, or need for emergency repair. Therefore, more
xperience needs to be gained before widely applying this
trategy. We are not suggesting that extensive occlusive or
ncomplicated bleeding lesions of the CFA be routinely
reated with stent grafts at this time, particularly when
he DFA is patent and this vital collateral would be
acrificed. Furthermore, the excellent patency rates of
ndarterectomy to treat occlusive lesions of the CFA are
ard to match. But in patients with severely scarred
roins from previous surgery and the morbidly obese,
ignificant wound healing problems can be encountered
ith a conventional surgical approach, and endovascular
reatment may be advantageous.
ONCLUSIONS
These results suggest that selective placement of PTFE-
overed stent grafts across the inguinal ligament to treat
rterial occlusive disease or bleeding adjacent to the CFA is
afe and effective with acceptable midterm patency. If rea-
onable long-term patency rates can be achieved in a larger
umber of patients, this strategy may become more widely
ccepted.
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This report by Calligaro et al regarding stent angioplasty
across the inguinal ligament, although a limited experience with a
select group of patients, lends promise to a technique previously
thought to be avoided at all costs. Crossing the inguinal ligament
was thought to lead to stent kinking, fracture, and certain occlu-
sion. There were also concerns about occlusion of the profunda
femoris artery when stenting into the area of the femoral artery and
the femoral bifurcation. These concerns regarding occlusion, en-
hanced hyperplasia, and the profunda femoris precluded most
physicians from using this technique despite less than ideal situa-
tions, including scarred groins or patients with active bleeding.
Open surgical techniques often required thromboendarterectomy
extending above the inguinal ligament to the external iliac artery or
distally into the second and third portion of the profunda.
However, the authors report a patency rate of90% at 2 years
with stent angioplasty that crosses the inguinal ligament. Calligaroare-metal stents. The proposed advantages of the endograft in
his location involved the persistent outward, radial force of the
itinol material with kink resistance. Similar advantages have been
ostulated with endografts to treat popliteal aneurysms. The cov-
red endograft also has obvious advantages when bleeding is an
ndication for treatment, as in the case of a pseudoaneurysm or
leeding from a percutaneous intervention. In these cases, open
epair can be a challenge due to the patient’s vascular anatomy
r medical condition, or both. Interestingly, there were no
ignificant complications involving the profunda femoris artery
n this experience.
Stent angioplasty across the inguinal ligament would also
llow the performance of more complex hybrid procedures using
ndovascular techniques into the common femoral artery, where
isease is often located. This is an important report, which will give
ascular surgeons some confidence in moving forward with en-
ograft stent deployment across the inguinal ligament when nec-
ssary to avoid scarred and hostile groins in high-risk patients.
